Marea Therapeutics Announces Publication in The Lancet of Positive Data from Phase 2a Clinical Trial of MAR001 for Cardiovascular Disease
Publication follows late-breaking oral presentation of Phase 2a results at the 93rd EAS Congress; MAR001 demonstrated approximately 53% placebo-adjusted mean reductions in remnant cholesterol and triglycerides at 12 weeks
Second publication of MAR001 preclinical results in eBioMedicine that demonstrate improved plasma lipid profiles
